Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia
Neurocognitive deficits in schizophrenia can reach 1 to 2 st and ard deviations below healthy controls . The comparative effect of typical and atypical antipsychotic medications on neurocognition is controversial , and based primarily on studies with small sample s and large doses of typical comparator medications . The present study assessed neurocognitive efficacy . It was hypothesized that olanzapine treatment would improve neurocognitive deficits to a greater degree than either risperidone or haloperidol treatment . This was a double-blind , r and omized , controlled , parallel study with neurocognition assessed at baseline , and 8 , 24 , and 52 weeks . Per protocol , the haloperidol arm was discontinued . Four hundred and fourteen in patients or out patients with schizophrenia and schizoaffective disorder were treated with oral olanzapine ( n = 159 ) , risperidone ( n = 158 ) , or haloperidol ( n = 97 ) . Individual domains ( executive function , learning and memory , processing speed , attention/vigilance , verbal working memory , verbal fluency , motor function , and visuospatial ability ) were transformed into composite scores and compared between treatment groups . At the 52-week endpoint , neurocognition significantly improved in each group ( p < 0.01 for olanzapine and risperidone , p = 0.04 for haloperidol ) , with no significant differences between groups . Olanzapine- and risperidone-treated patients significantly ( p < 0.05 ) improved on domains of executive function , learning/memory , processing speed , attention/vigilance , verbal working memory , and motor functions . Additionally , risperidone-treated patients improved on domains of visuospatial memory .  Haloperidol-treated patients improved only on domains of learning/memory . However , patients able to remain in treatment for the entire 52 weeks benefited more from olanzapine or risperidone treatment than haloperidol treatment
Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .